In February of 2008, Amira signed a global agreement with GlaxoSmithKline to develop, manufacture and commercialize FLAP inhibitors.

Commenting on the agreement, Dave Allen, SVP Respiratory Centre of Excellence in Drug Discovery, GlaxoSmithKline said: “The role of anti-leukotriene agents has been well validated in the treatment of respiratory diseases. We are very excited at entering into this global agreement with Amira to deliver novel therapies to patients based on this mechanism”.

Feb. 4, 2008 Amira Pharmaceuticals and GlaxoSmithKline enter global agreement for FLAP inhibitor program.
<more>

In January 2006, Amira signed a broad agreement with Roche covering a research alliance and an option to in-license two compounds from Roche.

“In the past, we referred to a ‘win-win’ alliance between pharma and biotech partners,” said Peter Hug, Roche’s Global Head of Pharma Partnering. “Through this new model, we have created a ‘win-win-win’ deal structure where three main players, Roche, Amira and the venture community, are all benefiting from a joint effort to develop potential new medicines for patients.”

Jan. 9, 2006 Roche and Amira Pharmaceuticals Announce Innovative Alliance Model
<more>

Business Development inquiries
Hari Kumar, Chief Business Officer
Tel: +1 858 228 4683
Email: hari.kumar@amirapharm.com